Latest news with #GlandPharmaLimited
New Indian Express
3 days ago
- Business
- New Indian Express
Unemployed youths get skill development training in Hyderabad
ADILABAD: The Hyderabad Tiger Conservation Society (HyTiCoS), in collaboration with Gland Pharma Limited and with support from the Pratham Foundation, launched a Skill Development Training Programme for unemployed rural youth. The training centre is in Shadnagar village, Rangareddy district. The curriculum covers automobile repair (car and bike mechanics), hotel management, housekeeping, beautician services, electrical work, food and beverage production, and marketing and sales. Students with a minimum education of 8th standard can apply for mechanic courses, while Plus Two is needed for other trades. The two-month training is free of cost, with accommodation and meals also provided. This ensures financial issues do not block access. HyTiCoS also promises 100% job placement, linking successful candidates directly to companies once they complete training.
Business Upturn
12-08-2025
- Business
- Business Upturn
Gland Pharma gets USFDA approval for Cangrelor injection with 180-day exclusivity
Gland Pharma Limited, a leading player in the generic injectable and ophthalmic pharmaceutical space, has received the green light from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Cangrelor for Injection, 50 mg/vial. The approved product is bioequivalent and therapeutically equivalent to the reference listed drug KENGREAL, developed by Chiesi USA Inc. Cangrelor Injection is prescribed as an adjunct to percutaneous coronary intervention (PCI) to lower the risk of periprocedural myocardial infarction (MI), repeat coronary revascularization, and stent thrombosis (ST) in patients who have not received a P2Y12 platelet inhibitor and are not being administered a glycoprotein IIb/IIIa inhibitor. One major highlight of this approval is that Gland Pharma will enjoy 180 days of generic drug exclusivity in the U.S. market — a key competitive advantage that could boost its revenue in the near term. According to IQVIA data, Cangrelor Injection recorded approximately USD 122 million in U.S. sales in the 12 months ending June 2025, highlighting the strong market potential for Gland Pharma's launch. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Business Upturn
04-06-2025
- Business
- Business Upturn
Gland Pharma gets USFDA nod for Angiotensin II Acetate Injection, secures 180-day exclusivity
By Markets Desk Published on June 4, 2025, 08:20 IST Gland Pharma Limited has received final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Angiotensin II Acetate Injection, 2.5 mg/mL. The injectable product is bioequivalent and therapeutically equivalent to the reference listed drug GIAPREZA®, developed by La Jolla Pharma LLC. It is indicated for increasing blood pressure in adults suffering from septic or other distributive shock. Importantly, Gland Pharma is the exclusive First-to-File applicant for this product and has secured 180 days of generic drug exclusivity in the U.S. market. According to IQVIA data, US sales of Angiotensin II Acetate Injection stood at approximately USD 58 million for the twelve months ending March 2025, highlighting the commercial opportunity for Gland Pharma. This approval further strengthens Gland Pharma's injectables portfolio and underscores its regulatory and filing capabilities in complex products. Markets Desk at
